GABA-A receptor is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-01-09. Numbers and descriptions here follow the published literature rather than marketing material.
Development took place at the Institute of Molecular Genetics of the Russian Academy of Sciences, where a series of short peptides were designed in the 1980s and 1990s. Selank was selected from variants of tuftsin that showed resistance to plasma peptidases. Russian regulatory approval covers it as an anxiolytic agent given intranasally. Outside that market the compound is normally handled as a research chemical rather than a medicine, and no widely recognised international pharmacopoeial monograph exists. The name Selank is a coined trade designation rather than a systematic chemical name.
Enzymatic stability motivates the extra three residues at the carboxyl end. Native tuftsin is cleaved quickly by circulating aminopeptidases and carboxypeptidases, which limits its duration of action and its usefulness as a tool compound. Extending the chain with proline-rich segments is a common design tactic because proline constrains the backbone and slows proteolysis. The same Pro-Gly-Pro motif appears in other Russian-developed peptides of the era. Whether the full seven-residue chain is required for activity, or whether it acts mainly as a prodrug releasing tuftsin, remains unresolved.
Outside its country of origin the compound is generally handled as a research chemical rather than an approved medicine. No regulatory approval from the United States Food and Drug Administration or the European Medicines Agency has been granted for human use. Identity and purity are normally checked by reverse-phase high-performance liquid chromatography, with mass spectrometry used to confirm the molecular mass. Lyophilised material is stored cold and desiccated, and repeated freeze-thaw cycles are avoided.
Published work on this peptide almost always uses intranasal delivery, with drops or a spray applied to the nasal mucosa. Some animal experiments have used subcutaneous or intraperitoneal injection, and a smaller number have compared routes directly. Oral administration is not a focus of the literature, because short peptides of this size are broken down by digestive enzymes and cross intestinal barriers poorly. How much of an intranasal dose reaches the bloodstream intact in humans remains an open question.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic heptapeptide | Tuftsin analogue with a C-terminal Pro-Gly-Pro tail |
| Amino acid sequence | Thr-Lys-Pro-Arg-Pro-Gly-Pro | Abbreviated TKPRPGP in most catalogues |
| Molecular mass | About 752 Da | Value for the free peptide |
| Solubility | Freely soluble in water | Aqueous solutions are kept cold and used promptly |
| Typical storage | -20 °C, dry, protected from light | Applies to the lyophilised powder before reconstitution |
Measuring peptide exposure inside the brain is technically difficult. Selank is degraded rapidly in plasma, and assays must separate intact peptide from fragments, which favors targeted mass spectrometry over immunoassays alone. Reported half-lives are short, on the order of minutes, so effects observed hours later are attributed to downstream signaling rather than to the parent compound. Blood-brain barrier permeability is debated and rarely quantified directly. Gaps include absent dose-response characterization, inconsistent reporting of purity, and almost no pharmacokinetic data from human participants.
Selank is studied chiefly as an animal-model anxiolytic with proposed secondary effects on memory and immune signaling. Reported mechanisms include modulation of the GABA-A receptor complex, inhibition of enkephalin-degrading enzymes, and shifts in monoamine turnover within limbic structures. Some experiments describe increased expression of brain-derived neurotrophic factor in the hippocampus after repeated dosing. No single molecular target has been confirmed, and the peptide does not bind any receptor with the selectivity typical of a conventional small-molecule drug. Mechanism therefore remains a set of hypotheses rather than an established pathway.
Pharmacokinetic data are sparse and largely derived from animal work. After intranasal administration the peptide appears in plasma within minutes, and reported half-lives are short, on the order of minutes to tens of minutes. Degradation proceeds through ordinary proteolytic cleavage into constituent amino acids and smaller fragments. Direct evidence that intact Selank reaches brain tissue in meaningful amounts is limited, and the extent of blood-brain barrier penetration is debated. Some authors argue that fragments, not the parent peptide, carry much of the observed activity.
Published clinical work is concentrated in Russian-language journals and generally involves small samples without independent replication. Systematic reviews in English note the shortage of randomised, placebo-controlled trials and the difficulty of verifying methods from translated reports. Outcome measures vary between studies, which complicates pooling of results. Interest in the compound as a cognitive or anxiolytic agent therefore rests on a thinner evidence base than the volume of citations suggests. Replication in well-powered trials with preregistered endpoints would be needed before firm conclusions about efficacy can be drawn.
Proposed mechanisms centre on the GABAergic system. Animal and tissue studies report changes in GABA-A receptor expression and reduced activity of GABA transaminase, the enzyme that degrades GABA. Effects on monoamine turnover, including serotonin and dopamine pathways, are also described, and a separate line of work links the peptide to increased expression of brain-derived neurotrophic factor in hippocampal tissue. Most of these findings come from rodent models and cell preparations. How the individual observations combine into a single coherent mode of action is not settled.
Selank is a synthetic heptapeptide developed in Russia. Its sequence is Thr-Lys-Pro-Arg-Pro-Gly-Pro, a seven-residue chain built around the natural tetrapeptide tuftsin. Researchers at the Institute of Molecular Genetics of the Russian Academy of Sciences first described the compound in the mid-1990s. The design combined the tuftsin core with an added Pro-Gly-Pro tail, a modification intended to extend the molecule's stability in biological fluids. Published work on the peptide has appeared mainly in Russian-language journals.
Reported activity for Selank centers on anxiolytic and nootropic effects. Russian clinical reports describe use in anxiety and in cognitive or attention-related complaints. Most of this evidence comes from studies conducted by the same research groups that developed the peptide. Independent replication in other countries remains limited, and no major Western regulatory agency has approved the compound for any indication. The gap between local reports and external verification is a recurring point in discussions of the peptide.
Olby's Australian lecture, March 2010 Salk Institute Press Release on the death of Francis Crick. The Francis Crick Papers – Profiles in Science, National Library of Medicine "Obituary: Francis Crick". The Times. London. 30 July 2004. Archived from the original on 7 November 2025. Francis Crick Obituary The Biochemist Miscellaneous
=== Death === Tsien died on August 24, 2016. Although the specific cause of death was not disclosed, it was reported that he died while on a bike trail in Eugene, Oregon. Prior to his death, Tsien had survived cancer and suffered a stroke in 2013. "He was ahead of us all," said Tsien's wife, Wendy. "He was ever the adventurer, the pathfinder, the free and soaring spirit. Courage, determination, creativity and resourcefulness were hallmarks of his character. He accomplished much. He will not be forgotten."
In 1961, Peter Mitchell proposed chemiosmosis as a cell's primary system of energy conversion. The mechanism, now ubiquitous in living cells, powers energy conversion in micro-organisms and in the mitochondria of eukaryotes, making it a likely candidate for early life. Mitochondria produce adenosine triphosphate (ATP), the energy currency of the cell used to drive cellular processes such as chemical syntheses. The mechanism of ATP synthesis involves a closed membrane in which the ATP synthase enzyme is embedded. The energy required to release strongly bound ATP has its origin in protons that move across the membrane. In modern cells, those proton movements are caused by the pumping of ions across the membrane, maintaining an electrochemical gradient. In the first organisms, the gradient could have been provided by the difference in chemical composition between the flow from a hydrothermal vent and the surrounding seawater, or perhaps meteoric quinones that were conducive to the development of chemiosmotic energy across lipid membranes if at a terrestrial origin.
Equine chorionic gonadotropin Gonadotropin preparations Human placental lactogen Pregnancy hormones Triple test, a screening test in pregnancy The Weight-Loss Cure "They" Don't Want You to Know About, a book written by Kevin Trudeau Chorionic+Gonadotropin at the U.S. National Library of Medicine Medical Subject Headings (MeSH) "History of pregnancy test". U.S. National Institutes of Health. Archived from the original on 2011-01-13. Retrieved 2011-01-10.
Prof. Ralser serves since 2019 as head of the Institute of Biochemistry at the Charité – Universitätsmedizin Berlin, Germany; as well as since 2022 as group leader at the University of Oxford, UK. He studied genetics and molecular biology in Salzburg, Austria. He completed his PhD in 2006 at the Max Planck Institute for Molecular Genetics in Berlin, Germany, studying neurodegenerative diseases. This was followed by a postdoctoral fellowship at the Vrije Universiteit Amsterdam, Netherlands, where he started to explore mass spectrometry. He returned to the MPI for Molecular Genetics in 2007 to become junior group leader, but in 2011 relocated his group to the University of Cambridge, UK. He relocated again, becoming group leader at the newly opened Francis Crick Institute in London in 2013 (senior group leader since 2019). His group moved to Oxford in 2022.
Sources: en.wikipedia.org
One advantage of benzodiazepines is that they alleviate anxiety symptoms much more quickly than antidepressants, and therefore may be preferred in patients for whom rapid symptom control is critical. However, this advantage is offset by the possibility of developing benzodiazepine dependence. APA does not recommend benzodiazepines for persons with depressive symptoms or a recent history of substance use disorder. APA guidelines state that, in general, pharmacotherapy of panic disorder should be continued for at least a year, and that clinical experience supports continuing benzodiazepine treatment to prevent recurrence. Although major concerns about benzodiazepine tolerance and withdrawal have been raised, there is no evidence for significant dose escalation in patients using benzodiazepines long-term. For many such patients, stable doses of benzodiazepines retain their efficacy over several years. Guidelines issued by the UK-based National Institute for Health and Clinical Excellence (NICE) carried out a systematic review using a different methodology and came to a different conclusion. They questioned the accuracy of studies that were not placebo-controlled. And, based on the findings of placebo-controlled studies, they do not recommend use of benzodiazepines beyond two to four weeks, as tolerance and physical dependence develop rapidly, with withdrawal symptoms including rebound anxiety occurring after six weeks or more of use.
== Clinical trials == Tedizolid proved its noninferiority to linezolid in two phase-III trials, known as the ESTABLISH trials. Tedizolid is the second treatment approved by the US Food and Drug Administration (FDA) under the Generating Antibiotic Incentives Now (known as the GAIN Act) federal law. New antibiotics manufactured under the act will be designated as a Qualified Infectious Disease Product (QIDP), allowing an expedited review by the FDA and an additional five years of market exclusivity.
The violent anti-Peruvian demonstrations in Ecuador and anti-Ecuadorian demonstrations in Peru, the mobilization of forces in both countries, everything made us hope that the armed conflict would break out in 1910, had it not been for the intervention of the United States, Brazil and Argentina. The hostilities between the two do not cease, which leads Ecuador in 1910 to establish a defensive alliance with Colombia, giving it 180,000 km2 of the Amazon area for payment, in exchange for strengthening a possible anti-Peruvian alliance between the two. A gesture that Colombia would betray in the eyes of Ecuador by ceding in 1922 to Peru, the common enemy, half of the territories ceded by it. In the middle of the 20th century, the degree of hostility would have increased to the point of a first armed confrontation in 1941, prompted by a seizure of Peruvian Amazonian territories at the hands of the Ecuadorian army, particularly the rubber zone. During the 2nd Peruvian-Ecuadorian War, the Porotillo Massacre broke out, whereby the Peruvian platoon, commanded by Alfredo Novoa Cava, was massacred in Cune by Ecuadorian troops on September 11, 1941, leaving only one survivor (the captain's nephew); This event, carried out in full truce, filled the Ecuadorian chiefs and officers with pride due to strong anti-Peruvian feelings, but not all the soldiers that made up the Ecuadorian detachment, who felt terrified by the fact that their superiors celebrated as one " victoria" a crime against humanity.
=== Odor === Feces possesses physiological odor, which can vary according to diet and health status. For example, meat protein is rich in the amino acid methionine, which is a precursor of the sulfur-containing odorous compounds listed below. The odor of human feces is suggested to be made up from the following odorant volatiles:
The energy associated with a particular wavefunction, perhaps the most important information contained in a wavefunction, can be extracted by solving the Schrödinger equation (above, Ψ is the wavefunction, E is the energy, and Ĥ is the Hamiltonian operator) in which an appropriate Hamiltonian operator is applied. In the various forms of the Schrödinger equation, the overall size of a particle's probability distribution increases with decreasing particle mass. For this reason, nuclei are of negligible size in relation to much lighter electrons and are treated as point charges in practical applications of quantum chemistry. Due to complex interactions which arise from electron-electron repulsion, algebraic solutions of the Schrödinger equation are only possible for systems with one electron such as the hydrogen atom, H2+, H32+, etc.; however, from these simple models arise all the familiar atomic (s,p,d,f) and bonding (σ,π) orbitals. In systems with multiple electrons, an overall multielectron wavefunction describes all of their properties at once. Such wavefunctions are generated through the linear addition of single electron wavefunctions to generate an initial guess, which is repeatedly modified until its associated energy is minimized. Thousands of guesses are often required until a satisfactory solution is found, so such calculations are performed by powerful computers. Importantly, the solutions for atoms with multiple electrons give properties such as diameter and electronegativity which closely mirror experimental data and the patterns found in the periodic table.
Sources: en.wikipedia.org
The four substrates of this enzyme are 4-hydroxybenzoic acid, reduced nicotinamide adenine dinucleotide (NADH), oxygen, and a proton. Its products are hydroquinone, oxidised NAD+, water, and carbon dioxide. Nicotinamide adenine dinucleotide phosphate can be used as an alternative cofactor. This enzyme is a flavin-containing monooxygenase that uses molecular oxygen as oxidant and incorporates one of its atoms into the starting material. The systematic name of this enzyme class is 4-hydroxybenzoate,NAD(P)H:oxygen oxidoreductase (1-hydroxylating, decarboxylating). This enzyme is also called 4-hydroxybenzoate 1-monooxygenase. This enzyme participates in benzoic acid degradation.
== Further reading == Higgins SJ, Hames BD (1999). Protein Expression: A Practical Approach. Oxford University Press. ISBN 978-0-19-963623-5. Baneyx, François (2004). Protein Expression Technologies: Current Status and Future Trends. Garland Science. ISBN 978-0-9545232-5-1.
One for the transfer of unfolded chains from water to the bilayer interface (referred to as the Wimley–White interfacial hydrophobicity scale). One for the transfer of unfolded chains into octanol, which is relevant to the hydrocarbon core of a bilayer. The website of Stephen H. White provides an example of whole residue hydrophobicity scales showing the free energy of transfer ΔG(kcal/mol) from water to POPC interface and to n-octanol. These two scales are then used together to make Whole residue hydropathy plots. The hydropathy plot constructed using ΔGwoct − ΔGwif shows favorable peaks on the absolute scale that correspond to the known TM helices. Thus, the whole residue hydropathy plots illustrate why transmembrane segments prefer a transmembrane location rather than a surface one.
== Potential health risks == The potential health impacts of MNPs vary based on factors such as particle size, shape, exposure time, chemical composition (e.g. enriched with heavy metals, polycyclic aromatic hydrocarbons, etc.), surface properties, and associated contaminants. Experimental and observational studies in mammals have reported a range of biological responses to micro and nanoplastic exposure. It is shown that MPs and NPs exposure have the following adverse effects:
Sources: en.wikipedia.org
Selank is a seven-amino-acid peptide built from the tuftsin sequence plus a Pro-Gly-Pro tail. It is produced by chemical synthesis rather than extracted from a natural source. The free peptide is usually supplied as a lyophilised powder or in an aqueous formulation.
Tuftsin is a natural tetrapeptide derived from the Fc portion of immunoglobulin G. Selank retains that tetrapeptide at its N-terminus and adds three residues to improve resistance to enzymatic breakdown. The relationship is structural, and the two molecules are not interchangeable in experimental work.
It holds a product registration in Russia for intranasal use as an anxiolytic. Registrations of that kind are not automatically accepted by regulators elsewhere. In most other countries it is treated as an unapproved substance or a research material.
Most published work uses intranasal application, either as drops or as a nasal spray. Injection routes appear in a smaller set of animal experiments. Oral use is uncommon in the literature because peptide breakdown and poor absorption limit this route.